Topics

SANOFI Company Profile

21:16 EST 22nd November 2019 | BioPortfolio

SANOFI concentrate their research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide:

  • DIABETES
  • CANCER
  • CARDIOVASCULAR DISEASES
  • INFECTIOUS DISEASES
  • ELEDERLY PATIENTS & AGING
  • OPHTHALMOLOGY
  • RARE DISEASES &
  • MULTIPLE SCLEROSIS

R&D PORTFOLIO

At the beginning of February 2013, SANOFI had 64 projects and vaccines under clinical development including 17 in phase 3 or submitted to healthcare authorities in the R&D portfolio of Sanofi.

Since the publication of the third quarter results, on October 25, 2012, Sanofi received the following regulatory decisions:

  • The approval of Zaltrap® (aflibercept) by the European Commission in metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.
  • The approval of Lyxumia® (lixisenatide) by the European Commission in type 2 diabetes and the submission to the FDA mid-December.
  • The FDA approval of Kynamro™ (mipomersen sodium, development partnership with Isis Pharmaceuticals) for the treatment of patients with Homozygous Familial Hypercholesterolemia.
  • The FDA accepted for review the supplemental biologics license application file seeking approval of Lemtrada™ (alemtuzumab, being developed in Multiple Sclerosis in collaboration with Bayer Healthcare) for the treatment of relapsing multiple sclerosis.
  • In addition, ENCORE, the second pivotal phase III trial of the investigational oral therapy, eliglustat, in Gaucher disease, met its primary efficacy endpoint of clinical stability compared to Cerezyme®.

Location

54, rue La Boétie
Paris
75008
France

Contact

Phone: +33 (0)1 53 77 40 00


News Articles [726 Associated News Articles listed on BioPortfolio]

Sanofi Selects Novartis Executive to Replace Retiring CEO

Brandicourt, who has helmed Sanofi since 2015, will retire from his CEO role this fall. Sanofi has a rule that its CEO cannot be over the age of 65.

Sanofi Reports Strong Second Quarter Driven by Dupixent Launch and Vaccine Sales

Sanofi reported overall net sales increased by 5.5% for the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.

Sanofi Gains US OTC Rights For Tamiflu To Treat Influenza

SOUTH SAN FRANCISCO (dpa-AFX) - Sanofi has signed an agreement with Roche, under which, Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketin...

Sanofi-Aktie im Aufwind: Ex-Novartis-Manager wird neuer CEO

Der französische Pharmakonzern Sanofi ist auf der Suche nach einem Nachfolger für Vorstandschef Olivier Brandicourt bei der Konkurrenz fündig geworden. Wie das Sanofi mitteilte, soll Novartis-Manag...

Jefferies belässt Sanofi auf 'Buy' - Ziel 90 Euro

Das Analysehaus Jefferies hat die Einstufung für Sanofi auf "Buy" mit einem Kursziel von 90 Euro belassen. Phase-II-Studiendaten zum Anti-IL-33 Antikörper REGN3500 von Sanofi und Regeneron hätten ....

Sanofi and Google to Establish Virtual Healthcare Innovation Lab Focused on AI-Enabled Datasets

French pharmaceutical company Sanofi and Google today announced its plan to establish a new virtual Innovation Lab that will leverage emerging data technologies to spur the transformation of healthcar...

Sanofi names Novartis leader CEO; Novartis appoints president

Sanofi erhält OTC-Rechte an Roche-Mittel Tamiflu in den USA

Von Cristina Roca PARIS (Dow Jones)--Die Pharmakonzerne Sanofi und Roche haben eine Vereinbarung für das Grippemedikament Tamiflu getroffen. Sanofi soll die Rechte für den freien Verkauf (OTC) von.....

Drugs and Medications [19 Associated Drugs and Medications listed on BioPortfolio]

Avalide [sanofi-aventis u.s. llc]

These highlights do not include all the information needed to use AVALIDE safely and effectively. See full prescribing information for AVALIDE. AVALIDE (irbesartan and hydrochlorothiazide) tablets, fo...

Methenamine hippurate [winthrop u.s.]

METHENAMINE HIPPURATE TABLETS, USP

Taxotere [sanofi-aventis u.s. llc]

These highlights do not include all the information needed to use TAXOTERE safely and effectively. See full prescribing information for TAXOTERE. TAXOTERE (docetaxel) injection, for intravenous use In...

Elitek [sanofi-aventis u.s. llc]

These highlights do not include all the information needed to use ELITEK safely and effectively. See full prescribing information for ELITEK. ELITEK (rasburicase) for injection, for intravenous useIn...

Xyzal [sanofi-aventis u.s. llc]

These highlights do not include all the information needed to use XYZAL safely and effectively. See full prescribing information for XYZAL. XYZAL (levocetirizine dihydrochloride) tablets, for oral use...

PubMed Articles [16 Associated PubMed Articles listed on BioPortfolio]

A review of Dengvaxia®: development to deployment.

Dengue is the world's most prevalent and important arboviral disease. More than 50% of the world's population lives at daily risk of infection and it is estimated more than 95 million people a year se...

ICER Can Do Better for Patients.

No outside funding supported the writing of this article. Mendez is president and CEO of the Asthma and Allergy Foundation of America, which receives greater than 25% of its funding to produce educati...

Effectiveness and safety of two different antithymocyte globulins used in induction therapy in kidney transplant recipients: a single center experience.

Antithymocyte globulin (ATG) is widely used as an induction therapy after kidney transplantation. The present study aimed to compare the effectiveness and safety of induction therapy between two ATG f...

A Randomized, Single-dose, Two-sequence, Two-period, Crossover Study to assess the Bioequivalence between Two Formulations of Clonazepam Tablet in Healthy Subjects.

Clonazepam is a benzodiazepine commonly prescribed to treat panic disorder, epilepsy, anxiety, depression and certain types of seizures. This study aimed to evaluate the bioequivalence between two for...

Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia.

The world's first dengue vaccine [Dengvaxia; Sanofi Pasteur] was licensed in 2015 and others are in development. Real-world evaluations of dengue vaccines will therefore soon be needed. We assessed fe...

Clinical Trials [80 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Primary objectives: - To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine. - To evaluate t...

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).

Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand

The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vac...

Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine

The overall aim of this study is to evaluate the safety and immunogenicity of Butantan Institute Trivalent Seasonal Influenza Vaccine in comparison with the Sanofi Trivalent Seasonal Influ...

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on v...

Companies [67 Associated Companies listed on BioPortfolio]

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

Sanofi Aventis Groupe

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SA...

Sanofi Pharmaceuticals Incorporated

Sanofi Pharmaceuticals are the U.S. subsidiary of Sanofi-Synthelabo, the global healthcare company. With annual sales in excess of $5.6 billion and 30,000 employees in more than 100 countries, Sanofi-...

Sanofi Pasteur MSD AG

Sanofi Pasteur MSD is the only European company dedicated exclusively to vaccines and was founded in 1994, as a joint venture between Sanofi Pasteur and Merck and Co. Inc.Sanofi Pasteur MSD develops v...

More Information about "SANOFI" on BioPortfolio

We have published hundreds of SANOFI news stories on BioPortfolio along with dozens of SANOFI Clinical Trials and PubMed Articles about SANOFI for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SANOFI Companies in our database. You can also find out about relevant SANOFI Drugs and Medications on this site too.

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record